The database of the Danish Renal Cancer Group
Authors Petersen AC, Søgaard M, Mehnert F, Larsen EH, Donskov F, Azawi NH, Kromann-Andersen B
Received 8 February 2016
Accepted for publication 7 March 2016
Published 25 October 2016 Volume 2016:8 Pages 725—729
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Professor Henrik Toft Sørensen
Astrid Christine Petersen,1 Mette Søgaard,2 Frank Mehnert,2 Erik Højkjær Larsen,3 Frede Donskov,4 Nessn H Azawi,5 Bjarne Kromann-Andersen6
1Department of Pathology, Aalborg University Hospital, Aalborg, 2Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, 3Department of Urology, Odense University Hospital, Odense, 4Department of Oncology, Aarhus University Hospital, Aarhus, 5Department of Urology, Zealand University Hospital, Roskilde, 6Department of Urology, Herlev and Gentofte Hospital, Copenhagen, Denmark
Aim of the database: The main purpose of the database of the Danish Renal Cancer Group (DaRenCaData) is to improve the quality of renal cancer treatment in Denmark and secondarily to conduct observational research.
Study population: DaRenCaData includes all Danish patients with a first-time diagnosis of renal cancer in the Danish National Pathology Registry since August 1, 2010.
Main variables: DaRenCaData holds data on demographic characteristics, treatments, and pathology collected through linkage to central registries and online registration of a few clinical key variables. Eight quality indicators have been selected for monitoring treatment quality and outcome after renal cancer.
Descriptive data: The incidence of renal cancer in Denmark has increased from 12.7 per 100,000 population-years in 2010–2011 to 15.9 per 100,000 population-years in 2014–2015. A total of 3,977 Danish patients with renal cancer have been enrolled in the database in the period August 1, 2010–July 31, 2015. The completeness of data registration has increased substantially since the first years of the database. A tendency toward smaller and less advanced tumors, less invasive surgery, and a shorter hospital stay was observed, while the postoperative morbidity and mortality remained stable. Concurrently, the 1-year survival has improved and was 84.1% in 2014–2015.
Conclusion: DaRenCaData provides valuable information on quality of and outcome after renal cancer treatment. Efforts to improve collection and registration of data are ongoing.
Keywords: kidney cancer, database, clinical quality, indicators, incidence, survival, observational research
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]